-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
New Products
| Cat.No. | Product Name | Information | Added |
|---|---|---|---|
| E6727 | GDC-4198 | Mar 26 2026 | |
| S9814 | BMS-986202 | BMS‑986202 is a potent, selective and orally active inhibitor of TYK2 that binds to the TYK2 pseudokinase domain (JH2) with an IC50 of 0.19 nM and a Ki of 0.02 nM. | Mar 24 2026 |
| E1584 | CCR6 inhibitor 1 | CCR6 inhibitor-1 is a potent and selective inhibitor of CCR6 with IC50 of 0.45 nM and 6 nM for monkey and human CCR6, respectively. It potently inhibits human B-cell migration and ERK phosphorylation, exhibiting potential as a treatment for autoimmune diseases. | Mar 24 2026 |
| E4769 | Aleniglipron (GSBR-1290) | Aleniglipron (GSBR‑1290) is a potent, orally available agonist of GLP‑1R that selectively activates the Gαs–cAMP signaling pathway without detectable β‑arrestin recruitment. | Mar 24 2026 |
| E1097 | Famitinib | Mar 23 2026 | |
| E6693 | PKUMDL-WQ-2101 | Mar 23 2026 | |
| P1273 | Ecnoglutide | Mar 23 2026 | |
| E6703 | MLT-985 | Mar 23 2026 | |
| E1475 | CFT1946 (Tagarafdeg) | CFT1946 (Tagarafdeg) is an orally bioavailable, CRBN‑based bifunctional degradation‑activating compound (BiDAC) that selectively targets mutant BRAFV600E for ubiquitin–proteasome–mediated degradation, with a DC50 of 14 nM in A375 melanoma cells. | Mar 23 2026 |
| E6751 | Sodium iodoacetate(Iodoacetic acid sodium salt) | Sodium iodoacetate(Iodoacetic acid sodium salt) is a specific, covalent inhibitor of glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) that blocks glycolytic flux by alkylating the catalytic cysteine residue in the active site, thereby exerting glycolysis‑inhibitory activity in cells and tissues. It also induces osteoarthritis‑like joint degeneration and related pain models in experimental animals. | Mar 19 2026 |
| E6756 | MOCAc-PLGL(Dpa)AR | MOCAc-PLGL(Dpa)AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is a FRET-based fluorescent peptide substrate for MMPs including MMP-7 (matrilysin), MMP-2, and MMP-9, where the MOCAc fluorophore is quenched by Dpa until cleavage at the Gly-Leu bond produces >10-fold fluorescence increase for activity assays. | Mar 19 2026 |
| E6456 | PF-07248144(Prifetrastat) | PF‑07248144 (Prifetrastat) is a potent and selective catalytic inhibitor of KAT6A and KAT6B that exhibits durable antitumor activity and the potential to treat metastatic breast cancer. | Mar 16 2026 |
| F2677 | β Actin Antibody [H22G2] | ACTB,beta Actin,beta Actin Loading Control,beta-Actin,β-Actin | Mar 12 2026 |
| E5879 | Elinzanetant | Elinzanetant (NT-814; BAY3427080) is a nonhormonal dual antagonist of NK1/NK3 receptor that reduces GnRH pulsatility by blocking neurokinin B (NK3) and substance P (NK1) effects on the reproductive axis in KNDy neurons. | Mar 12 2026 |
| E1593 | Camlipixant | Camlipixant (BLU-5937) is a potent, selective, non-competitive antagonist that target P2X3 homotrimeric receptor, with an IC50 of 25 nM for hP2X3 homotrimeric form. | Mar 12 2026 |
| E6702 | Opitor-0 | Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase), that regulates cristae remodeling and cytochrome c release, with an IC50 of 3 μM. | Mar 10 2026 |
| E8328 | Ro24-7429 | Ro24-7429 is a benzodiazepine derivative that acts as a potent, orally active antagonist of HIV-1's Tat transactivator protein, disrupting viral replication by inhibiting Tat-mediated transactivation of the HIV-1 long terminal repeat (LTR) promoter. It also inhibits RUNX1 (runt-related transcription factor 1), contributing to antifibrotic effects by reducing fibrosis markers in models like bleomycin-induced pulmonary fibrosis, alongside anti-inflammatory properties. | Mar 10 2026 |
| P1259 | Cagrilintide | Cagrilintide is a long-acting acylated amylin analogue functioning as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). Its dual action promotes satiety, slows gastric emptying, and reduces food intake through brain-mediated pathways with the potential to treat obesity. | Mar 10 2026 |
| E4671 | ML334 | ML334 (LH601A) is a potent, cell-permeable activator of NRF2 that disrupts the Keap1-NRF2 protein-protein interaction by binding the Keap1 Kelch domain with a Kd of 1 μM, promoting NRF2 nuclear translocation and antioxidant gene expression. | Mar 08 2026 |
| E6698 | STL1267 | STL1267 is a potent agonist of REV-ERB, with Ki of 0.16 µM for REV-ERBα that crosses the blood-brain barrier, enhancing NCoR corepressor recruitment to repress circadian and metabolic genes. | Mar 08 2026 |
| E6697 | PACMA 31 | PACMA 31 is an irreversible, orally active inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. It covalently binds PDI's active-site cysteines, inhibiting reductase/isomerase activity in a dose- and time-dependent manner per insulin aggregation assays. | Mar 01 2026 |
| E6661 | Ontunisertib | Ontunisertib (AGMB-129) is an oral, GI-restricted small molecule inhibitor of ALK5 (TGFβR1), exhibiting the potential to treat fibrostenosing Crohn’s disease (FSCD). It potently blocks pro-fibrotic TGFβ signaling locally in the GI tract via high first-pass metabolism. | Mar 01 2026 |
| E6659 | TYRA-200 | TYRA-200 is an orally bioavailable inhibitor of FGFR1/2/3 that exhibits potential to address clinically observed acquired resistance alterations in FGFR2, such as molecular brake and gatekeeper mutations. | Mar 01 2026 |
| F2463 | FADD Antibody [P17H10] | Feb 28 2026 | |
| F5322 | BRCC36 Antibody [M5D3] | Feb 28 2026 | |
| F7401 | SMARCD3/BAF60C Antibody [C13A4] | Feb 28 2026 | |
| F0346 | Phospho-PERK (Thr980) Antibody [E16F3] | Feb 28 2026 | |
| F3023 | IL-6 Antibody [F4K18] | IL-6 | Feb 28 2026 |
| F3061 | IL-1β Antibody [J24M1] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F3067 | IL-1β Antibody [H12N7] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F3557 | Phospho-EGF Receptor (Tyr1045) Antibody [F16D14] | Feb 28 2026 | |
| F3443 | Phospho-p130 (Ser672) Antibody [E21C6] | Feb 28 2026 | |
| F4814 | SOX10 Antibody [E22E2] | Feb 28 2026 | |
| F4857 | Apolipoprotein E Antibody [L10K14] | Feb 28 2026 | |
| F4146 | Phospho-Stat5 (Tyr694) Antibody [L6J15] | Feb 28 2026 | |
| F3968 | Phospho-EGFR (Tyr1101) Antibody [A24A1] | Feb 28 2026 | |
| E4770 | Jedi2 | Jedi2 is an activator of the Piezo1 channel that binds to mouse Piezo1 protein with a Kd of 2770 μM. | Feb 27 2026 |
| E6712 | PYCR1-IN-1 | PYCR1-IN-1 (compound 4) is an inhibitor of pyrroline-5-carboxylate reductase 1 (PYCR1) with an IC50 of 8.8 µM. It significantly reduce the levels of proline within a breast cancer cell line and exhibits anti-cell proliferation effect. | Feb 26 2026 |
| E6708 | HQ461 | HQ461 is a molecular glue degrader that promotes CDK12-DDB1-CUL4-RBX1 interaction, causing polyubiquitination and degradation of Cyclin K (CCNK). HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. | Feb 26 2026 |
| E6637 | YCT529 | YCT-529 is a selective antagonist of retinoic acid receptor alpha (RARα) developed as a pyrrole-linked analog that potently inhibits RARα with an IC50 of 1.2 nM and greater than 300-fold selectivity over RARβ and RARγ. It also serves as oral non-hormonal male contraceptive effectively reduces sperm counts in mice and non-human primates by targeting the retinoid signaling pathway essential for spermatogenesis. | Feb 11 2026 |
| E6630 | NT-0527 | NT-0527 is a potent, specific, and brain-penetrant inhibitor of the NLRP3 inflammasome with oral bioavailability and demonstrated efficacy in an in vivo model of inflammation. | Feb 08 2026 |
| S8827 | Diprovocim | Diprovocim is a potent synthetic agonist that activates the human TLR1/TLR2 heterodimer with an EC50 of 110 pM in THP-1 cells. It also exhibits significant potential as an immune adjuvant. | Feb 04 2026 |
| E6670 | AC-4-130 | AC-4–130 is a potent, selective inhibitor of the STAT5 SH2 domain that directly binds to STAT5, blocking its phosphorylation, dimerization, and nuclear translocation. It acts by disrupting STAT5-dependent gene transcription, effectively reducing pathological STAT5 activity in acute myeloid leukemia (AML). | Feb 03 2026 |
| E6675 | MC3482 | MC3482 is a specific, cell-permeable inhibitor of SIRT5 that mitigates microglia-induced neuroinflammation and neuronal apoptosis by regulating Annexin-A1 succinylation. It significantly improves long-term sensorimotor and cognitive function, exhibiting potential for anti-ischemic stroke treatment. | Feb 03 2026 |
| E6509 | AR420626 | AR420626 is a selective agonist of FFAR3 (GPR41) with an IC50 of 117 nM, that prevents serotonin-induced circular muscle relaxation ex vivo and defecation in vivo. | Feb 03 2026 |
| E6626 | STAT3-IN-3 | STAT3-IN-3 is a potent, selective chemical inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that has shown efficacy in mitigating drug resistance. | Feb 03 2026 |
| E8326 | HNHA | HNHA (N-hydroxy-7-(2-naphthylthio) heptanomide) is a cell-permeable inhibitor of histone deacetylase (HDAC) activity, a key enzyme in gene expression and carcinogenesis with an IC50 of 100 nM. It also exhibits anti-tumor activity both in vitro and in vivo. | Feb 03 2026 |
| E6726 | N-Hydroxysuccinimide | N-Hydroxysuccinimide (HOSu; 1-Hydroxy-2,5-pyrrolidinedione) is a crucial reagent that forms NHS esters via DCC-mediated carboxylic acid activation. These esters enable covalent protein/antibody coupling to surfaces through primary amine reactions. It also modifies microfluidic SPR sensors for bacterial pathogen detection. | Feb 01 2026 |
| A2177 | Anti-mouse IFNγR (CD119)-Invivo | Anti-mouse IFNγR (CD119)-Invivo reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. CD119 heterodimerizes with IFNγ receptor 2 (AF-1) to form the IFNγR, a Class II cytokine receptor. | Jan 26 2026 |
| A2178 | Anti-mouse/human IL-5-Invivo | Anti-mouse/human IL-5-Invivo reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA. | Jan 26 2026 |
| E1822 | Acoramidis hydrochloride | Acoramidis hydrochloride (AG10 hydrochloride) is an orally active, selective kinetic stabilizer of WT-transthyretin (TTR) and V122I mutant transthyretin (TTR), providing effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). | Jan 22 2026 |
| E6699 | Opiranserin hydrochloride | Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively. | Jan 22 2026 |
| S9883 | RMC-5552 | RMC-5552 is a selective bi-steric inhibitor of mTORC1, with the potential for treating mTORC1-activated tumors. It potently inhibits mTORC1-mediated phosphorylation of pS6K and p4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. | Jan 22 2026 |
| A2176 | Anti-mouse CD8α (53-6.7)-Invivo | Anti-mouse CD8α (53-6.7)-Invivo reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). | Jan 20 2026 |
| E6671 | CMPD-39 | CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays. | Jan 19 2026 |
| E6515 | ML-60218 | ML-60218 is a broad-spectrum inhibitor of RNA polymerase III (pol III), with an IC50 of 32 μM for Saccharomyces cerevisiae and 27 μM for human pol III. ML-60218 disrupts pre-assembled viroplasms and impedes the formation of new ones, acting independently of de novo transcription of cellular RNAs. | Jan 19 2026 |
| F4050 | Phospho-AKT1 (Thr450) Antibody [H24E24] | Jan 16 2026 | |
| F2613 | Phospho-TAK1 (Ser439) Antibody [F17C11] | Jan 16 2026 | |
| F3409 | POLDIP2 Antibody [N1K14] | Jan 16 2026 | |
| F0402 | Phospho-TAK1 (Thr184/187) Antibody [G4C5] | Jan 16 2026 | |
| F5127 | CNBP Antibody [E10D2] | Jan 16 2026 | |
| F4751 | Phospho-MEK1 (Ser298) Antibody [L22P14] | Jan 16 2026 | |
| F4738 | FXR1 Antibody [G5P16] | Jan 16 2026 | |
| F4918 | Phospho-Akt1 (Ser129) Antibody [K23C4] | Jan 16 2026 | |
| P1262 | Eloralintide (LY-3841136) | Eloralintide (LY 3841136) is an AMYR agonist with potential applications in type 2 diabetes and obesity research. | Jan 14 2026 |
| E6411 | RP03707 | RP03707 is a PROTAC molecule designed to degrade KRASG12D, consisting of three components: a KRASG12D inhibitor (, red), a linker (black), and an E3 ligase ligand (blue). | Jan 14 2026 |
| E6653 | AR-C118925XX | AR-C118925XX is a P2Y2 receptor antagonist. It reduces ATP-induced IL-6 production and p38 phosphorylation. In mice, AR-C118925XX attenuates Bleomycin -induced dermal fibrosis. Additionally, it suppresses ATP-stimulated tumor growth. | Jan 14 2026 |
| E6651 | HGC652 | HGC652 is a TRIM21-dependent molecular glue degrader that binds the E3 ubiquitin ligase TRIM21 (Kd ≈ 0.06 µM) to induce a TRIM21–NUP98 ternary complex, driving the ubiquitination and selective degradation of nuclear pore complex proteins like NUP155, leading to nuclear pore collapse and cancer cell death. | Jan 14 2026 |
| P1269 | Pegcetacoplan acetate | Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis). | Jan 13 2026 |
| E8319 | Ro 48-8071 fumarate | Ro 48-8071 fumarate is a potent, selective inhibitor of 2,3-oxidosqualene cyclase (OSC) (IC50 = 6.5 nM), a key enzyme downstream of HMG-CoA reductase that catalyzes lanosterol formation in cholesterol biosynthesis. It reduces intracellular cholesterol levels without the feedback upregulation of HMG-CoA reductase seen with statins, providing a distinct, self-limiting regulatory loop for lowering LDL-C. Additionally, it also exhibits significant anti-cancer properties by inducing apoptosis and disrupting cell signaling in cancer models. | Jan 13 2026 |
| F4944 | SCG10/Stathmin-2 Antibody [D11B18] | Jan 12 2026 | |
| F4375 | Na+/H+ Exchanger-1 Antibody [K9D3] | Jan 12 2026 | |
| F3707 | Na(+)/K(+)-transporting ATPase (pan α subunit) Antibody [G11K19] | ATP1A1/ATP1A2/ATP1A3/ATP1A4 | Jan 12 2026 |
| F4620 | MMP-3 Antibody [K11K15] | Jan 12 2026 | |
| F2603 | Wnt3 and Wnt3a Antibody [J20B9] | Jan 12 2026 | |
| E6564 | VG-3927 | VG‐3927 is a potent, selective, and brain-penetrant agonist of TREM2 that induces anti-inflammatory microglial activation and has the potential to treat Alzheimer's disease (AD). | Jan 12 2026 |
| F1719 | MBP tag Antibody [E2A2] | Maltose Binding Protein,MBP tag,MBP-probe | Jan 12 2026 |
| F2110 | Otoferlin Antibody [J18F12] | Jan 12 2026 | |
| E8330 | NIC3 | NIC3 is a selective inhibitor of nucleus accumbens-associated protein 1 (NAC1), a BTB/POZ domain-containing transcription corepressor overexpressed in cancers. It binds the conserved Leu-90 residue in NAC1's BTB domain, disrupting homodimerization essential for nuclear body formation and stability. | Jan 05 2026 |
| E8325 | Quadrol | Quadrol (N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine, EDTP) is an immunostimulant which is considered as a potentially useful active molecule for accelerating wound healing. Quadrol can form a complex with Ca²⁺, mediate the entry of Ca²⁺ into macrophages, and stimulate macrophage activation. | Jan 05 2026 |
| E8327 | DHBS | DHBS (Sodium 3,5-dichloro-2-hydroxybenzenesulphonate) is used in conjunction with 4-aminoantipyrine (4-AAP) and hydrogen peroxide (H2O2) for chromogenic quantitation of uric acid in serum and urine samples. | Jan 05 2026 |
| E6635 | MC3138 | MC3138 is a selective activator of SIRT5 and inhibits proliferation in SIRT5-low PDAC cell lines and organoids by restoring SIRT5-mediated desuccinylation and deacetylation. | Jan 04 2026 |
| E0853 | 360A | 360A stabilizes G-quadruplex structures and inhibits telomerase activity, showing an IC50 of 300 nM in TRAP-G4 assays. | Dec 31 2025 |
| A2175 | Anti-mouse CD11c-Invivo | Anti-mouse CD11c-Invivo reacts with mouse CD11c, the most widely used defining marker for murine dendritic cells (DCs). CD11c is also known as integrin alpha-X (Itgax) and CD11 antigen-like family member C. | Dec 30 2025 |
| E6667 | JNJ-9350 | JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research. | Dec 24 2025 |
| E8329 | VQW-765 | VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies. | Dec 24 2025 |
| E1789 | Asundexian | Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, asundexian exhibits an IC50 of 1 nM against human FXIa. | Dec 24 2025 |
| E6656 | STAT3-IN-13 | STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research. | Dec 24 2025 |
| E5872 | BBO-10203 | BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research. | Dec 24 2025 |
| E8324 | GE11 | GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research. | Dec 21 2025 |
| E0850 | DPhPC | DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties. | Dec 14 2025 |
| F4670 | Keratin 18 Antibody [M2J10] | Dec 12 2025 | |
| F4438 | GPX1/2 Antibody [L20K22] | Dec 12 2025 | |
| F1643 | Glutathione Antibody [A11G7] | Dec 12 2025 | |
| F2030 | 5-hydroxymethylcytosine Antibody [B13H23] | Dec 12 2025 | |
| F2031 | VSV-G tag Antibody [N12B16] | VSV Glycoprotein,VSV-G tag | Dec 12 2025 |
| F2238 | Influenza A Virus M2 Protein Antibody [L21L24] | Influenza A M2,Influenza A Virus M2 Protein | Dec 12 2025 |
| F3018 | IFN-γ Antibody [A4P20] | IFN-γ,Interferon gamma | Dec 12 2025 |
| F3039 | Acetyl-CoA Carboxylase 2 Antibody [E20M20] | Dec 12 2025 | |
| F2701 | Thymine Dimer Antibody [E15K19] | Dec 12 2025 | |
| F3241 | Phospho-β Catenin (Ser675) Antibody [D16B23] | Dec 12 2025 | |
| F3306 | Phospho-Nephrin (Tyr1217) Antibody [L5D2] | Dec 12 2025 | |
| F3647 | Phospho-EGFR (Tyr992) Antibody [F20E14] | EGFR (phospho Y992),Phospho-EGF Receptor (Tyr992) | Dec 12 2025 |
| F4192 | Caspase-1 Antibody [C2H20] | Dec 12 2025 | |
| F4779 | Mannose Receptor Antibody [E13A19] | Dec 12 2025 | |
| F2860 | Phospho-NAK/TBK1 (Ser172) Antibody [G18L12] | NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172) | Dec 12 2025 |
| F4919 | Myc tag Antibody [A14H15] | Dec 12 2025 | |
| E8323 | Emeramide | Emeramide functions as a thiol-based redox antioxidant and chelates heavy metals. | Dec 10 2025 |
| E0848 | Pinealon | Pinealon is a tripeptide exhibiting neuroprotective effects. This peptide inhibits reactive oxygen species (ROS) buildup and blocks ERK 1/2 activation. It enhances functional activity of key brain tissue cellular components while decreasing spontaneous cell death rates. Studies demonstrate Pinealon's protective effects against prenatal hyperhomocysteinemia in rat offspring. | Dec 10 2025 |
| E6646 | BMS-986260 | BMS-986260 is an orally active immuno-oncology agent that inhibits TGFβR1 with an IC50 of 1.6 nM. It shows selectivity for TGFβR1 compared to TGFβR2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGFβ-induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively. | Dec 09 2025 |
| E6560 | naperiglipron | Naperiglipron (LY3549492) (Example 2) acts as a glucagon-like peptide 1 receptor (GLP-1R) agonist, exhibiting an EC50 of 1.14 nM at hGLP-1R. In GLP-1R knock-in mouse models, it reduces blood glucose levels. The compound shows PDE10A1 enzyme inhibitory activity (IC50: 7.43 μM) and displays weak hERG inhibition. Naperiglipron has potential applications in type II diabetes mellitus (T2DM) and obesity studies. | Dec 08 2025 |
| E6639 | Auceliciclib (AU3-14,Ulecaciclib ) | Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with Ki values of 0.62 μM for CDK2/Cyclin A, 0.2 nM for CDK4/Cyclin D1, 3 nM for CDK6/Cyclin D3, and 0.63 μM for CDK7/Cyclin H. This compound demonstrates blood-brain barrier penetration and favorable pharmacokinetic properties. | Dec 04 2025 |
| P1231 | Mazdutide (IBI362, LY330567) | Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D). | Dec 04 2025 |
| E6643 | SS-3091 | SS‑3091 is a potent inhibitor of pan‑KRas that targets the interaction interfaces of KRas, destabilizing critical KRas–protein complexes and thereby blocking its downstream signaling pathways. SS‑3091 effectively inhibits KRas‑driven signaling in multiple cancer cell lines, including those harboring G12D, G12V, and G13D mutations, leading to reduced ERK and AKT phosphorylation. | Dec 04 2025 |
| E5927 | Mito-LND (Mito-Lonidamine) | Mito-LND (Mito-Lonidamine) is a mitochondria-targeted derivative of lonidamine conjugated with a triphenylphosphonium cation that selectively accumulates in cancer cell mitochondria due to their high membrane potential. It potently inhibits oxidative phosphorylation (OXPHOS) by disrupting respiratory complexes I and II, stimulating ROS production and Prx3 oxidation while suppressing AKT/mTOR/p70S6K signaling. | Dec 04 2025 |
| E6511 | ADT-1004 | ADT-1004 is an orally bioavailable prodrug of ADT-007, that acts as a first-in-class selective inhibitor of pan-RAS with potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models. | Dec 04 2025 |
| E6526 | MCB-294 | MCB-294 is a pan-KRAS inhibitor that targets both active (GTP-bound) and inactive (GDP-bound) KRAS states, exhibiting Kd values of about 1 pM and 10 nM, respectively. It shows preferential inhibition of KRAS over NRAS and HRAS. The compound inhibits proliferation of hTERT-HPNE cells harboring G12D, G12C, G12V, G12S, G13D, and wild-type KRAS variants, with IC50 values around 700 nM. MCB-294 triggers apoptosis in KRAS-mutated tumors and demonstrates activity against KRASG12C inhibitor-resistant cancer cells while modulating the tumor immune microenvironment. This compound serves as a research tool for pancreatic, colorectal, and lung cancer investigations. | Dec 04 2025 |
| E5936 | FT895 | FT895 inhibits HDAC11 with an IC50 of 3 nM. | Dec 04 2025 |
| E6647 | Bireociclib (XZP-3287,CDK4/6-IN-2) | CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6. | Dec 04 2025 |
| E6638 | VS-7375 (GFH375) | VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model. | Dec 04 2025 |
| E6517 | PKN1 | PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumor cell migration and related physiological processes. | Dec 02 2025 |
| E6521 | HRS‑5346 | Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders. | Dec 02 2025 |
| E6578 | AS1708727 | AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK. | Dec 02 2025 |
| E6498 | Atebimetinib (IMM-1-104) | Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects. | Dec 02 2025 |
| E6636 | DY268 | DY268 is a farnesoid X receptor (FXR) antagonist with an IC50 of 7.5 nM. In cellular assays, it inhibits FXR transactivation with an IC50 of 468 nM. This compound has applications in drug-induced liver injury (DILI) research. | Nov 25 2025 |
| E6634 | Thiethylperazine | Thiethylperazine is a phenothiazine derivative that acts as an oral dopamine D2-receptor and histamine H1-receptor antagonist. This compound functions as an ABCC1 activator and has been shown to decrease amyloid-β (Aβ) accumulation in mice. It exhibits anti-emetic, antipsychotic, and antimicrobial properties. | Nov 25 2025 |
| E6565 | Ofirnoflastum | Ofirnoflast (Ofirnoflastum) inhibits serine/threonine-protein kinase Nek7 and exhibits anti-inflammatory activity. | Nov 24 2025 |
| E6572 | AD1058 | AD1058 is an orally bioavailable ATR inhibitor with blood-brain barrier permeability (IC50 = 1.6 nM). It demonstrates antitumor effects through inhibition of tumor cell proliferation, induction of cell cycle arrest, and promotion of apoptosis. This compound is applicable for studies involving advanced malignancies and brain metastases. | Nov 24 2025 |
| E6588 | LY3509754 | LY3509754 (IL-17A inhibitor 1) inhibits IL-17A, showing IC50 values of <9.45 nM in alphalisa assay and 9.3 nM in HT-29 cells. | Nov 24 2025 |
| E4617 | Gly-β-MCA | Gly-β-MCA is a bile acid derivative that functions as a stable, orally active, and intestine-specific farnesoid X receptor (FXR) antagonist with potential therapeutic applications in metabolic diseases. | Nov 21 2025 |
| E1219 | CSN5i-3 | CSN5i-3 is a selective, orally bioavailable CSN5/Jab1 inhibitor that demonstrates potent activity in suppressing CSN-mediated Cul1 deneddylation, exhibiting an IC50 of 5.8 nM. | Nov 21 2025 |
| E8318 | T6167923 | T6167923 is a selective MyD88-dependent signaling pathway inhibitor that directly interacts with the Toll/IL-1 receptor (TIR) domain of MyD88, preventing its homodimerization. This compound demonstrates inhibitory effects on NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity and exhibits anti-inflammatory properties, with IC50 values of 2.7 μM (IFN-γ), 2.9 μM (IL-1β), 2.66 μM (IL-6), and 2.66 μM (TNF-α). | Nov 21 2025 |
| E1892 | FM4-64 | FM4-64 is a very lipophilic, water-soluble styryl dye that specifically binds to cell membranes and inner membrane organelles to produce fluorescence upon insertion into lipid bilayers. It is widely used as a marker for endocytic and exocytic membrane structures, tracking vesicle trafficking in live cells with minimal aqueous background fluorescence. | Nov 21 2025 |
| E1162 | GLPG0974 | GLPG0974 is a potent and selective antagonist of the human free fatty acid receptor 2 (FFA2/GPR43) with an IC50 of 9 nM and also inhibits SCFA‐induced neutrophil activation and migration. | Nov 21 2025 |
| E1888 | NIM811 ((Melle-4)cyclosporin) | NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally administered dual inhibitor targeting mitochondrial permeability transition and cyclophilin, demonstrating strong in vitro antiviral activity against hepatitis C virus (HCV) . | Nov 21 2025 |
| E4757 | Setidegrasib (ASP3082) | ASP3082 (Setidegrasib; KRAS G12D inhibitor 17) is a PROTAC degrader targeting KRAS(G12D) with a DC50 of 38 nM. It effectively inhibits growth in various KRAS(G12D)-mutated cancer cell lines, including pancreatic (PK-59, HPAC) and colorectal (GP2d, GP5d) with IC50 values ranging from 3.6 to 29 nM. | Nov 20 2025 |
| E5832 | BBI-2779 | BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumor growth and prevents drug resistance. | Nov 20 2025 |
| E5858 | Chiglitazar (Carfloglitazar) | Chiglitazar (Carfloglitazar) is a potent dual agonist of PPARα and PPARγ with EC50 values of 1.2 μM and 0.08 μM, respectively, and also activates PPARδ with an EC50 of 1.7 μM. It effectively improves insulin resistance and corrects dyslipidemia in monosodium L-glutamate (MSG)-induced obese rats. | Nov 20 2025 |
| E5859 | Acivicin hydrochloride | Acivicin hydrochloride (AT-125 hydrochloride) is the hydrochloride salt of Acivicin, a natural antibiotic produced by Streptomyces sviceus. It is a potent inhibitor of γ-glutamyl transpeptidase (GGT), an enzyme that initiates glutathione catabolism to cysteine. Acivicin also exhibits anti-cancer and anti-parasitic properties. | Nov 20 2025 |
| E5860 | 20-HETE | 20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome P450-derived metabolite of arachidonic acid that plays a dual role in blood pressure regulation. It lowers blood pressure by inhibiting sodium reabsorption and promoting natriuresis in the kidneys, but also raises blood pressure by sensitizing vascular smooth muscle to constrictors, increasing myogenic tone, and inducing endothelial dysfunction. Additionally, 20-HETE stimulates endothelial angiotensin-converting enzyme (ACE), activating a prohypertensive renin-angiotensin-aldosterone system (RAAS) feedback loop that contributes to hypertension and vascular remodeling. | Nov 20 2025 |
| E1983 | BAY-850 | BAY-850 is a potent and isoform-selective inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain, with an IC50 of 166 nM in TR-FRET assays. It induces ATAD2 bromodomain dimerization and effectively blocks its interaction with acetylated histones in vitro. | Nov 20 2025 |
| E2989 | AZD5904 | AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects. | Nov 20 2025 |
| E5915 | Moracin O | Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. Moracin O demonstrates potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1) with an IC50 value of 6.76 nM in a cell-based HRE assay. Moracin O attenuates reactive oxygen species (ROS) generation triggered by oxygen-glucose deprivation (OGD). Moracin O also exhibits neuroprotective and anti-inflammatory effects. | Nov 20 2025 |
| E5946 | C12FDG | C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside). | Nov 20 2025 |
| E4747 | BMS-986408 | BMS-986408 is a first-in-class dual inhibitor of DGKα and DGKζ, exhibiting IC₅₀ values of 0.0003 μM and 0.002 μM for DGKα and DGKζ lipid kinase activity, respectively. It potentiates T cell–receptor signaling and T-cell activation, enhancing the effectiveness of both PD-1 and CAR T-cell therapy in preclinical models. | Nov 20 2025 |
| E6600 | 3FAx-Neu5Ac | 3Fax-Neu5Ac is a fluorinated sialic acid analogue that inhibits sialyltransferase activity, reduces cellular sialylation, and leads to decreased MHC expression and suppression of myoblast fusion, thereby demonstrating potential in regulating skeletal muscle cell differentiation. | Nov 20 2025 |
| E6603 | USP5-IN-1 | USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) with a Kd of 2.8 μM. It competitively blocks ubiquitin binding to the ZnF-UBD domain, suppressing USP5 catalytic activity and ubiquitin chain hydrolysis, with potential applications as a chemical probe and therapeutic agent in USP5-related cancers. | Nov 20 2025 |
| E6614 | FABPs ligand 6 (MF6) | FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). | Nov 20 2025 |
| E6610 | GPX4-IN-5 | GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research. | Nov 20 2025 |
| E2949 | Talarozole (R115866) | Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy. | Nov 20 2025 |
| E1154 | DS18561882 | DS18561882 is a potent, tricyclic coumarin-based inhibitor of MTHFD2 with an IC50 of 0.0063 μM, exhibiting significant selectivity over the cytosolic isozyme MTHFD1. It also effectively inhibits tumor growth in mouse xenograft models in vivo. | Nov 20 2025 |
| P1253 | Allo-aca (ARV-1803) | Allo-aca (ARV-1803) is a synthetic peptide that functions as a specific antagonist of the leptin receptor, effectively blocking leptin signaling in both in vitro and in vivo. It also demonstrates potential therapeutic applications in the treatment of ophthalmic diseases. | Nov 20 2025 |
| P1267 | CIRC-014 | CIRC-014 is an orally bioavailable cyclin A/B RxL macrocyclic inhibitor. CIRC-014 displays robust anti-tumor activity in chemo-resistant small cell lung cancer (SCLC) PDX models and induces SAC activation and apoptosis in vivo. | Nov 20 2025 |
| E6608 | HSK31858 | HSK31858 is a reversible inhibitor of DPP-1. It promotes the amelioration of neutrophilic inflammation, demonstrating efficacy and safety in reducing exacerbation frequency in adults with bronchiectasis. | Nov 20 2025 |
| E1963 | ARV-393 | ARV-393 is a highly potent, orally bioavailable BCL6 PROTAC degrader. ARV-393 promotes rapid BCL6 degradation through the cells ubiquitin-proteasome pathway. ARV-393 demonstrates DC50 and GI50 values <1 nM in numerous DLBCL and BL cell lines. | Nov 19 2025 |
| F5072 | Cox1 Antibody [N11K4] | Nov 12 2025 | |
| F1062 | E2F-1 Antibody [N6L18] | E2F 1,E2F1,E2F-1 | Nov 12 2025 |
| F0405 | Phospho-c-Fos (Ser32) Antibody [H14J15] | Nov 12 2025 | |
| F4416 | PGC1α/β Antibody [H5N22] | Nov 12 2025 | |
| F4661 | Keratin 20 Antibody [L17C14] | Nov 12 2025 | |
| F4337 | Claudin 7 Antibody [M7D16] | Nov 12 2025 | |
| F4131 | c-Fos Antibody [B8E19] | Nov 12 2025 | |
| F4147 | HER2/ErbB2 Antibody [G18G3] | Nov 12 2025 | |
| F2178 | CXCR4 Antibody [G11H20] | CXCR4,CXCR-4 | Nov 12 2025 |
| E6559 | GS-1427 | GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease. | Nov 12 2025 |
| F3553 | Phospho-SMAD2 (Ser245/250/255) Antibody [H4M3] | Nov 10 2025 | |
| F3893 | Phospho-PERK (Thr982) Antibody [A3P5] | Nov 10 2025 | |
| F4139 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M10N15] | Nov 10 2025 | |
| F4089 | Phospho-EGF Receptor (Tyr1173) Antibody [E8J4] | Nov 10 2025 | |
| F4188 | PGC-1α Antibody [J17F10] | Nov 10 2025 | |
| F0348 | Phospho-Smad1/5 (Ser463/465) Antibody [H6D11] | Nov 10 2025 | |
| E6539 | SHOC2–RAS PPI-IN-1 | SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor that disrupts the SHOC2-RAS protein-protein interaction. It exhibits an IC50 of 0.048 μM and a KD of 0.065 μM against NRASQ61R. The compound inhibits the SMP phosphatase complex, resulting in elevated CRAFS259 phosphorylation and subsequent blockade of the MAPK signaling pathway (evidenced by reduced pMEK and pERK levels). This inhibition induces tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 serves as a research tool for investigating NRASQ61R-mutant malignancies including melanoma and colorectal cancer. | Nov 10 2025 |
| F0256 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M9C2] | Phospho-VEGF Receptor 2 (Tyr1175),VEGF Receptor 2 (phospho Y1175) | Nov 10 2025 |
| F1920 | Tryptophan/Tyrosine/Phenylalanine Hydroxylase Antibody [A9C1] | Nov 10 2025 | |
| F2955 | MIF Antibody [M24J2] | Nov 10 2025 | |
| E6589 | 2BAct | 2BAct is a potent, orally bioavailable eIF2B activator exhibiting high selectivity (EC50 = 33 nM). It mitigates neurological impairments induced by persistent integrated stress response. This compound demonstrates blood-brain barrier penetration with enhanced solubility and pharmacokinetic properties compared to ISRIB trans-isomer. | Nov 09 2025 |
| E5972 | ZINC00784494 | ZINC00784494 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases viability, and attenuates AKT phosphorylation in SUM149 cells. This compound demonstrates promising research potential for inflammatory breast cancer (IBC) investigations. | Nov 03 2025 |
| E6536 | Antalarmin hydrochloride | Antalarmin hydrochloride is an orally active, non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist exhibiting a Ki value of 1 nM. This compound inhibits CRH-induced ACTH secretion and attenuates CRH-mediated and novelty-induced anxiety-like behaviors in preclinical models. Additionally, antalarmin hydrochloride demonstrates anti-inflammatory activity in arthritis models and reduces stress-induced gastric ulceration associated with irritable bowel syndrome. | Nov 03 2025 |
| E6534 | Safusidenib | Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective inhibitor of mutant IDH1. It demonstrates potent inhibition against mutant IDH1 while showing minimal activity against the wild-type enzyme. This compound exhibits antitumor effects in chondrosarcoma models. In vitro assays without preincubation, it inhibits IDH1R132H and IDH1R132C with IC50 values of 15 nM and 130 nM, respectively. | Nov 03 2025 |
| E6576 | Valiltramiprosate | ALZ-801 is an orally bioavailable small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor. As a valine-conjugated prodrug of tramiprosate, it demonstrates significantly enhanced pharmacokinetic properties and gastrointestinal tolerability compared to the parent compound. This agent represents an optimized therapeutic candidate for Alzheimer's disease treatment. | Nov 03 2025 |
| E5971 | ZINC00640089 | ZINC00640089 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases cell viability, and reduces AKT phosphorylation levels in SUM149 cells. This compound shows promising research potential for inflammatory breast cancer (IBC) studies. | Oct 28 2025 |
| E6541 | PolQi2 | PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, PolQi2 demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies. | Oct 28 2025 |
| E6522 | HRS-9821 | PDE3/4-IN-2 (Compound 1) functions as a dual inhibitor targeting both PDE3 and PDE4 enzymes, exhibiting IC50 values of 0.13 nM for PDE3A and 50 nM for PDE4B1. This compound demonstrates potential for investigating PDE-associated pathologies including asthma, chronic obstructive pulmonary disease, sepsis, and nephritis. | Oct 22 2025 |
| E1076 | Linperlisib | Linperlisibis a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10). | Oct 15 2025 |
| E6577 | 1-Naphthohydroxamic acid | 1-Naphthohydroxamic acid (Compound 2) demonstrates potent and selective inhibition of HDAC8 (IC50 = 14 μM), exhibiting significantly greater selectivity for HDAC8 compared to class I HDAC1 and class II HDAC6 (IC50 >100 μM). This compound does not elevate global histone H4 acetylation levels nor decrease total intracellular HDAC activity. Additionally, 1-naphthohydroxamic acid has been shown to promote tubulin acetylation. | Oct 15 2025 |
| F0871 | eNOS/NOS Type III Antibody [L17A10] | eNOS,eNOS/NOS Type III,NOS3 | Oct 13 2025 |
| F2144 | Granzyme B Antibody [B18E4] | Oct 13 2025 | |
| F2333 | Phospho-p70 S6K (Thr421/Ser424) Antibody [E5J12] | p70 S6K phospho Thr421 Ser424,Phospho-p70 S6 Kinase (Thr421/Ser424) | Oct 13 2025 |
| F2518 | Oct4 Antibody [K18A18] | Oct3/4,Oct-3/4,Oct4,Oct-4,OCT-4 [POU5F1] | Oct 13 2025 |
| F2523 | Cleaved Caspase-3 Antibody [G2J3] | Caspase 3,Caspase-3 | Oct 13 2025 |
| F0232 | LATS1 Antibody [A5C10] | LATS1,LATS1/WARTS | Oct 13 2025 |
| F2690 | V5 Tag Antibody [L19E11] | Paramyxovirus SV5 Pk,V5,V5 Epitope Tag,V5 Tag,V5-Probe,V5-Tag | Oct 13 2025 |
| F3854 | Periostin Antibody [C16F13] | Oct 13 2025 | |
| F4011 | CD4 Antibody [F12H10] | Oct 13 2025 | |
| F4076 | PDGFR α Antibody [E14D18] | Oct 13 2025 | |
| F4084 | β-Catenin Antibody [E8L3] | Oct 13 2025 | |
| F4087 | Phospho-Akt1 (Ser473) Antibody [K10L8] | Oct 13 2025 | |
| F4133 | COX IV Antibody [A4F21] | Oct 13 2025 | |
| F4181 | MMP-2 Antibody [C12L21] | Oct 13 2025 | |
| F4220 | Zap-70 Antibody [E5E23] | Oct 13 2025 | |
| F4250 | Neurofilament-H Antibody [P21P23] | Oct 13 2025 | |
| F4988 | PSMA Antibody [A11C13] | Oct 13 2025 | |
| F3994 | LAMP2A Lysosome Marker Antibody [M18B14] | Oct 13 2025 | |
| F4221 | STAT5 Antibody [B9G7] | Oct 13 2025 | |
| F3245 | IRF1 Antibody [H12G6] | Oct 13 2025 | |
| E1242 | Barbadin | Barbadin is a selective β-arrestin/β2-adaptin interaction inhibitor with IC50 values of 19.1 μM (β-arrestin1) and 15.6 μM (β-arrestin2). It inhibits agonist-induced endocytosis of β2-adrenergic, V2-vasopressin, and angiotensin-II type-1 receptors. Additionally, Barbadin exhibits pro-apoptotic activity. | Oct 12 2025 |
| E6574 | NLRP3 | NLRP3/aim2-in-2 (compound 8) is a novel potent inhibitor exhibiting species-specific effects on NLRP3 and AIM2 inflammasome-dependent cell death, with an IC50 value of 0.2392 μM. | Oct 10 2025 |
| E6573 | Neuropathiazol | Neuropathiazol is a neuronal differentiation inducer that specifically promotes the neuronal differentiation of multipotent hippocampal neural progenitor cells. | Oct 10 2025 |
| E1955 | TNG348 | TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers . | Oct 10 2025 |
| E6596 | LAP | LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) serves as a free radical initiator. The radicals generated by LAP during bioprinting exhibit potential cytotoxicity and mutagenicity. Furthermore, LAP concentration influences the mechanical strength of 3D-printed scaffolds. The typical concentration range employed for curing is 0.05%-1%. Optimal mechanical properties and biocompatibility are achieved at 0.1% concentration, demonstrating the highest elastic modulus. | Sep 29 2025 |
| E6514 | BI033 | BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease. | Sep 29 2025 |
| E1829 | Calderasib (MK-1084) | Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research. | Sep 25 2025 |
| E7074 | Sulfo-NHS-LC-Biotin sodium | Sulfo-NHS-LC-Biotin sodium is a biotinylated amine-reactive ester compound that cannot cross the intact blood-retinal barrier. This reagent serves as a useful tool for evaluating vascular permeability in both cerebral and retinal vasculature. | Sep 24 2025 |
| E5854 | XYD049 | XYD049 (compound 7d) is a CRBN-based molecular glue targeting GSPT1 (DC50=19 nM), applicable for studying MYC-driven castration-resistant prostate cancer (CRPC). It demonstrates potent growth inhibition of 22Rv1 cells (IC50=7 nM) and exhibits in vivo antitumor activity. This compound downregulates CRPC-associated oncogenes (AR, AR-v7, PSA, c-Myc) in 22Rv1 cells. Structurally, it consists of: 1) a molecular glue linker (NH2-C5-NH-Boc), 2) a CRBN-recruiting E3 ligase ligand (Thalidomide 4-fluoride), and 3) a GSPT1-targeting moiety (GSPT1 ligand-1). The E3 ligase ligand-linker combination forms conjugate 158. | Sep 24 2025 |
| E1968 | BBO-8520 | BBO-8520 is a covalent small molecule inhibitor that selectively targets KRAS G12C with high oral bioavailability. It functions as both a KRAS G12C (OFF) inhibitor and a blocker of KRAS G12C (ON) signaling. This compound inhibits cellular proliferation by binding to GTP-bound KRAS G12C (ON), thereby preventing RAS-RAF1 interaction and promoting the transition to the inactive (OFF) state. | Sep 24 2025 |
| E6407 | CD2665 | CD2665 is an orally bioavailable selective antagonist of RAR-β and RAR-γ, exhibiting dissociation constants (Kd) of 306 nM for RAR-β and 110 nM for RAR-γ. | Sep 24 2025 |
| E6410 | Peptide 4 | Peptide 4 is a complex synthetic peptide molecule commonly used as a research chemical or therapeutic agent due to its potential to mimic biological peptides and modulate specific molecular targets. | Sep 16 2025 |
| S9959 | Zotizalkib | Zotizalkib(TPX-0131) is a compact macrocyclic potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations with an IC50 of 1.4 nM for wild-type ALK. It exhibits antitumor efficacy and can be used in non–small cell lung cancer research. | Sep 14 2025 |
| E4727 | TYRA-300 | TYRA-300 , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations. | Sep 14 2025 |
| E6547 | crinecerfont | crinecerfont (SSR-125543) is a selective antagonist of the corticotropin-releasing factor type 1 receptor (CRF1R). It lowers elevated adrenal androgens and steroid precursors in adolescents with congenital adrenal hyperplasia (CAH), including those with 21-hydroxylase deficiency. | Sep 14 2025 |
| E6580 | Nusinersen | Nusinersen is an 18-mer, 2′-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide used for treating spinal muscular atrophy (SMA). It binds specifically to the intronic splice silencer N1 (ISS-N1) site in intron 7 of SMN2 pre-mRNA, blocking the binding of splicing repressors hnRNP A1/A2. This promotes inclusion of exon 7 during splicing, restoring full-length SMN protein production in SMA patients. | Sep 12 2025 |
| E6581 | Mipomersen | Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH). | Sep 12 2025 |
| E1887 | Sisunatovir hydrochloride | Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection. | Sep 07 2025 |
| F0016 | V5-Tag Antibody [K5J22] | Paramyxovirus SV5 Pk,V5,V5 Epitope Tag,V5 Tag,V5-Probe,V5-Tag | Sep 05 2025 |
| F2801 | MALT1/MLT Antibody [P2K2] | MALT1,MALT1/MLT | Sep 05 2025 |
| F2459 | Caspase-3 p12 Antibody [N15D21] | caspase-3 p11,Caspase-3 p12 | Sep 05 2025 |
| F4083 | CD206/MRC1 Antibody [K13P18] | Sep 05 2025 | |
| F2516 | mTOR Antibody [L10A18] | Sep 05 2025 | |
| E6459 | Phaclofen | Phaclofen is a selective antagonist of GABAB receptor. Phaclofen is a peripheral and central baclofen antagonist that is used in determining the physiological significance of central and peripheral bicuculline-insensitive receptors with which GABA and (-)-baclofen interact. | Sep 03 2025 |
| S8027 | GW1929 | GW1929 is a potent and selective agonist of PPARγ with a pKi of 8.84 for human PPARγ and pEC50 of 8.56 and 8.27 in human and murine receptors, respectively. It exhibits potential clinical benefits in managing diabetic dyslipidemias and cardiovascular risk factors through its lipid-lowering effects and improved insulin sensitivity mediated by PPARγ activation. | Sep 01 2025 |
| E6478 | ML115 | ML115 is a molecular probe and a highly potent, selective agonist of STAT3 with an EC50 of 2.0 nM. It can be used in research on cancer, wound healing, cardiomyopathy, and inflammatory diseases. | Aug 26 2025 |
| E5885 | JG-2016 | JG-2016 is a potent and selective inhibitor of HAT1, with an IC50 of 14.8 μM and a binding KD of 22.5 μM for the HAT1:Rbap46 complex. It exhibits anti-proliferative activity with EC50 of 10.4 μM, 29.8 μM, and 1.9 μM in HCC1806, FICC1937, and A549 cells, respectively. JG-2016 significantly suppresses tumor growth in an A549 xenograft model. | Aug 26 2025 |
| E5817 | Sevasemten | Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy. | Aug 26 2025 |
| A2173 | Anti-mouse L-Selectin (CD62L)-InVivo | Anti-mouse L-Selectin (CD62L)-InVivo reacts with mouse CD62L also known as L-selectin and MEL-14. CD62L is a 76 kDa glycoprotein and a member of the selectin family. | Aug 22 2025 |
| A2174 | Anti-mouse/human CD44-InVivo | Anti-mouse/human CD44-InVivo reacts with human and mouse CD44 also known as Hermes, HCAM, and Pgp-1. CD44 is an 80-95 kDa glycoprotein that is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells. | Aug 22 2025 |
| E5989 | PZL-A | PZL-A is a activator of mitochondrial DNA (mtDNA) synthesis. PZL-A restores wild-type-like activity to mutant forms of polymerase γ (POLγ) with 160 nM for A467T and 20 nM for G848S. In cellular systems, PZL-A stimulates mtDNA synthesis, promoting oxidative phosphorylation complex biogenesis and improving cellular respiration. PZL-A is promising agent for relieving POLG disease and other severe conditions linked to depletion of mtDNA. | Aug 20 2025 |
| E6444 | SSTC3 | SSTC3 is a potent activator of casein kinase 1α (CK1α) with a Kd of 32 nM that inhibits WNTsignaling with an EC50 of 30 nM. It attenuates CRC cell growth through CK1α-dependent WNT pathway inhibition, offering an improved therapeutic index for targeting WNT-driven tumors. | Aug 20 2025 |
| E5992 | VLS-1272 | VLS-1272 is an orally bioavailable, potent, ATP non-competitive, microtubule-dependent, and highly selective inhibitor of KIF18A with an IC50 of 41 nM. It induces mitotic defects with strong anti-mitotic, anti-cancer, and anti-proliferative effects, leading to dose-dependent tumor growth inhibition and can be used for the study of cancers with high chromosomal instability. | Aug 20 2025 |
| E4693 | AC-73 | AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research. | Aug 20 2025 |
| E5970 | PF-07853578 | PF-07853578 (Example 11) is a degrader of Patatin-Like Phospholipase Domain-Containing Protein 3(PNPLA3) with an EC50 of 5.2 nM. It may be useful for the treatment and prevention of liver diseases, including fatty liver, nonalcoholic fatty liver disease (NALFD), nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma. | Aug 20 2025 |
| E6502 | USP7-IN-1 | USP7-IN-1 (Example 2) is a selective and reversible inhibitor of USP7 with an IC50 of 77 Μm and exhibits antiproliferative activity, inhibiting the growth of HCT116 colorectal cancer cells with a GI50 of 67 μM. | Aug 20 2025 |
| F3784 | RHEB Antibody [L24C4] | Aug 19 2025 | |
| F3880 | NUMB Antibody [D4K1] | Aug 19 2025 | |
| F3830 | CX3CL1/Fractalkine Chemokine Domain Antibody [K3M15] | Aug 19 2025 | |
| F3971 | Alcohol Dehydrogenase Antibody [C8G21] | Aug 19 2025 | |
| F0603 | Phospho-YB1 (Ser102) Antibody [D17A16] | Aug 19 2025 | |
| F3780 | KLF4 Antibody [K21G5] | Aug 19 2025 | |
| F3225 | MCP1 Antibody [M3B19] | CCL2 (MCP-1),CCL2/MCP1 | Aug 19 2025 |
| F3741 | Monocyte + Macrophage Antibody [E17C4] | Aug 19 2025 | |
| F3764 | Phospho-Hsp27 (Ser82) Antibody [M1P19] | Hsp27 (phospho S82),Phospho-HSP27 (Ser82),Phospho-HSP27 (Ser82) II | Aug 19 2025 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.